• Precision BioSciences disclosed new, late-breaking ELIMINATE-B trial data on PBGENE-HBV at the EASL Congress 2026; results were presented there.
• Liver biopsy findings supported the therapy’s intended ability to disable the viral reservoir driving chronic hepatitis B, a result the company framed as a field first.
• Blood biomarker readouts aligned with the biopsy signal, reinforcing evidence of sustained antiviral activity across treated patients.
• Safety profile remained manageable with no dose-limiting toxicities; infusion-related reactions were most common, with mitigation steps introduced for hypotension and liver-enzyme spikes.
• Next steps include enrolling more patients, collecting additional biopsy data, preparing for nucleoside-analog withdrawal, and selecting a dosing schedule for a later-stage expansion; updates targeted by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260526374454) on May 27, 2026, and is solely responsible for the information contained therein.